Cardiorenal interactions: insights from the ESCAPE trial.

By A. Nohria, V. Hasselblad, A. Stebbins, D. Pauly, G. Fonarow, M. Shah, C. Yancy, Robert M. Califf, L. Stevenson, James A. Hill. Journal of the American College of Cardiology, 2008

605 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Nephrology

View Paper: https://www.semanticscholar.org/paper/9099e6ca5a00851f4f592baaf82eb15646c6c7a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. S. Anker
2. M. Gheorghiade

In Nephrology

1. R. Bellomo
2. Claudio Ronco
3. Sean M. Bagshaw
4. M. Gheorghiade
5. John A. Kellum

Citations in the corpus

• Acute heart failure syndromes (2009, background): “Worsening renal function occurs in 20% o 30% of patients during hospitalization (65,66).”
• Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative (2009, background): “Most studies are retrospective, secondary, and/or post hoc analyses from large databases 18 or clinical trials of drug therapy.(19,20) The term ‘WRF’ has been used to describe the acute and/or sub-acute changes in kidney function in patients ADHF or ACS.”
• Cardiorenal syndrome. (2008, positive): “In this setting, where one would ntuitively consider hemodynamic issues to be dominant, he ESCAPE (Evaluation Study of Congestive Heart Failre and Pulmonary Catheterization Effectiveness) trial (56) ound no link between any pulmonary artery cathetereasured hemodynamic variables and serum creatinine ”